anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
Nuvalent · pitchdeck

Nuvalent | Investor Presentation Deck | 42 slides

42 pages · 4 arc beats · 2 loops

Pitchdeck Download JSON
Unlock

Nuvalent | Investor Presentation Deck | 42 slides

Nuvalent · 2024-01
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
— No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.
—

Deck intelligence map

4
coverage by narrative range · generated from this deck JSON
Narrative range 10 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem 1 slides 100% 1/1 slides 100% 1/1 slides · 4 hits
— 0/1 slides
100% 1/1 slides 100% 1/1 slides 100% 1/1 slides · 2 hits 100% 1/1 slides Solution 7 slides 100% 7/7 slides 100% 7/7 slides · 38 hits
— 0/7 slides
71.4% 5/7 slides 71.4% 5/7 slides 100% 7/7 slides · 9 hits 28.6% 2/7 slides Market Sizing 1 slides 100% 1/1 slides 100% 1/1 slides · 5 hits
— 0/1 slides
— 0/1 slides
— 0/1 slides
100% 1/1 slides 100% 1/1 slides Team 1 slides 100% 1/1 slides 100% 1/1 slides · 5 hits
— 0/1 slides
— 0/1 slides
— 0/1 slides
100% 1/1 slides · 2 hits
— 0/1 slides

Slide inventory

42
every slide · same image gating as the playbook
01
Slide 1
Includes company logo, date, and tagline.front_matter
Open slide detail
02
other
Open slide detail
03
The slide uses a 2x2 grid layout to summarize key company metrics.summarize
Open slide detail
04
The slide uses a list of four key pillars of the company's methodology.present_solution
Open slide detailBeat · Solution
05
The slide uses a chronological structure to demonstrate operational momentum.show_traction
Open slide detailBeat · Solution
06
The slide uses a timeline to connect corporate strategy to specific clinical trial milestones.plan_implementation
Open slide detailBeat · Solution
07
The slide features a split layout with a left-hand column for advisors/board and a right-hand grid for the leadership team, plus a footer highlighting 12 prior other
Open slide detailBeat · Solution
08
The slide uses a Gantt-style visualization to represent drug development stages.plan_implementation
Open slide detailBeat · Solution
09
The slide uses a structured table to contrast two distinct patient populations (ALK+ vs ROS1+) across three lines of therapy (1L, 2L, 3L+).compare_peers
Open slide detailBeat · ProblemLoop · Cost Of Inaction
10
Uses a 'cite_precedent' framework to validate the strategy by comparing it to the established success of Osimertinib.present_solution
Open slide detailBeat · SolutionLoop · Cost Of Inaction
11
The chart visualizes the dominance of Alectinib and Crizotinib in the current market landscape.size_opportunity
Open slide detailBeat · Market SizingLoop · Cost Of Inaction
12
Slide 12 of a pitch deck, likely from Nuvalent.establish_context
Open slide detailLoop · Jobs To Be Done
13
The slide uses a timeline-based journey map to contrast standard treatments with unmet clinical needs.frame_problem
Open slide detailLoop · Jobs To Be Done
14
The slide uses a matrix-style comparison to highlight the superior/differentiated profile of the 4th generation inhibitor NVL-655.compare_peers
Open slide detailLoop · Jobs To Be Done
15
The slide presents two distinct scientific data sets: an IC50 dot plot for in vitro activity and a bar chart for in vivo tumor regression.present_solution
Open slide detail
16
Includes a formula for Selectivity index and a legend for various compound mutations.present_solution
Open slide detail
17
The slide provides a detailed breakdown of patient enrollment across different dose cohorts (15mg to 200mg QD) for the NVL-655 clinical trial.analyze_data
Open slide detail
18
Data cut-off: 8 Aug 2023. Includes detailed breakdown of prior ALK TKI therapies.analyze_data
Open slide detail
19
Slide presents two distinct clinical data visualizations: a PK line chart and a waterfall plot for mutation clearance.show_traction
Open slide detail
20
Data cut-off: 8 Aug 2023. Includes detailed breakdown of response by mutation type and prior treatment history.analyze_data
Open slide detail
21
Clinical trial data (ALKove-1) showing efficacy of NVL-655 in NSCLC patients.analyze_data
Open slide detail
22
Swimmer plot visualization of clinical trial patient outcomes.show_traction
Open slide detail
23
Includes before/after MRI scans for two specific patient cases.show_traction
Open slide detail
24
Data cut-off: 8 Aug 2023. N=93 treated patients.analyze_data
Open slide detail
25
The slide uses a three-column layout to segment the market by treatment line (3L+, 2L, 1L) and contrast current standards of care with the proposed solution's bpresent_solution
Open slide detail
26
The slide outlines a clinical trial design with specific patient cohorts (2a-2d) and study objectives.plan_implementation
Open slide detail
27
The slide uses a sidebar 'AT A GLANCE' to summarize key program attributes.establish_context
Open slide detail
28
The slide uses a timeline-based framework to contrast 1L and 2L+ treatment landscapes and their associated clinical challenges.present_framework
Open slide detail
29
The slide uses a matrix-like comparison to highlight the unique value proposition of NVL-520 compared to standard-of-care drugs.compare_peers
Open slide detail
30
Includes specific pharmacological data points for NVL-520 vs competitors like Crizotinib, Entrectinib, Lorlatinib, Taletrectinib, and Repotrectinib.present_solution
Open slide detail
31
The slide presents a summary of a clinical trial, including patient eligibility criteria and a breakdown of patient enrollment by dose cohort.show_traction
Open slide detail
32
Data presented in two side-by-side tables summarizing patient characteristics and treatment history.analyze_data
Open slide detail
33
Includes a summary table of ORR and best response, and a waterfall plot showing individual patient tumor regression.show_traction
Open slide detail
34
Includes clinical trial data (ARROS-1 Phase 1) with specific patient subgroup outcomes.show_traction
Open slide detail
35
Data as of 13 Sep 2022. N=35 patients.analyze_data
Open slide detail
36
The chart shows pharmacokinetic data (NVL-520 concentration over time) compared against target efficacy thresholds for different ROS1 variants.show_traction
Open slide detail
37
Uses a side-by-side comparison framework to contrast 2L+ (salvage) and 1L (front-line) market opportunities.argue_timing
Open slide detail
38
The slide outlines a multi-cohort clinical trial design with specific patient segments based on prior treatment history.plan_implementation
Open slide detail
39
The slide uses a 'ribbon' style callout box on the right for key product attributes.present_solution
Open slide detail
40
The slide uses three distinct chart types to demonstrate superiority in three key pharmacological areas.present_solution
Open slide detail
41
The slide uses a timeline framework to connect current clinical progress to a 2026 goal of product approval.plan_implementation
Open slide detail
42
front_matter
Open slide detail